SCHEMBL5635569

SCHEMBL5635569

CC1CNCCN1S(=O)(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
KMT2A Q03164 5/20 0.52
PRKACA P17612 4/20 0.52
PRKD3 O94806 3/20 0.52
PRKACG P22612 3/20 0.52
PRKACB P22694 3/20 0.52
PRKCZ Q05513 3/20 0.52
PRKCD Q05655 3/20 0.52
PRKCG P05129 2/20 0.52
PRKCB P05771 2/20 0.52
PRKCA P17252 2/20 0.52
PRKCH P24723 2/20 0.52
PRKCI P41743 2/20 0.52
PRKCE Q02156 2/20 0.52
PRKCQ Q04759 2/20 0.52
PRKD1 Q15139 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714375 1.00 L3MBTL1 (0.58) L3MBTL1KMT2APRKACAPRKD3PRKACG
SCHEMBL16442259 1.00 L3MBTL1 (0.58) L3MBTL1KMT2APRKACAPRKD3PRKACG
SCHEMBL3718844 0.85 PSEN1 (0.61) KMT2APRKACAPRKD3PRKACGPRKACB
SCHEMBL7892632 0.85 PSEN1 (0.61) KMT2APRKACAPRKD3PRKACGPRKACB
Hydrochloric Acid SCHEMBL1429753 0.84 PSEN1 (0.59) KMT2APRKACAPRKD3PRKACGPRKACB
SCHEMBL7895826 0.83 PRKACA (0.52) KMT2APRKACAPRKD3PRKACGPRKACB
SCHEMBL4563889 0.83 PRKACA (0.49) KMT2APRKACAPRKD3PRKACGPRKACB
SCHEMBL28092047 0.83 AKR1C3 (0.58) L3MBTL1KMT2APRKACAPRKD3PRKACG
SCHEMBL10042202 0.82 MMP1 (0.65) L3MBTL1SMN1; SMN2TSHRRAB9AHTT
SCHEMBL22501842 0.82 TRPV4 (0.54) L3MBTL1KMT2ASMN1; SMN2MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
CN-101941953-B Nitrogenous heterocyclic substituted hydrazide compounds as well as preparation methods and applications thereof SHENZHEN XIANGYA BIOPHARMACEUTICAL INST 2013-04-10 CN disclosed
US-8404690-B2 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2013-03-26 US disclosed
CN-101941953-A Nitrogenous heterocyclic substituted hydrazide compounds as well as preparation methods and applications thereof SHENZHEN XIANGYA BIOPHARMACEUTICAL INST 2011-01-12 CN disclosed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142391-A1 Piperazine-2-carboxamide derivatives P2RX5, P2RX2, NPY5R L3MBTL1 4633/4885KMT2A 396/4885PRKACA 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.